Biogen Idec, Inc. (NASDAQ: BIIB) reported Q2 EPS of $1.36, $0.01 worse than the analyst estimate of $1.37. Revenue for the quarter came in at $1.21 billion versus the consensus estimate of $1.18 billion.

Sees FY11 adj-EPS above $5.70, which compares to the Street estimate of $5.85.

Earnings Guidance Hot Earnings